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c o mm e n ta r y

case study

Myriad stands alone
Jacob S Sherkow & Christopher Scott
Myriad took no prisoners on its way to the top of the molecular diagnostics field. That strategy is unlikely to endure.
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yriad Genetics began in 1991 as a small
University of Utah startup interested in
the then-novel arena of diagnostic genetic testing. After winning a highly publicized race to
sequence the BRCA1 and BRCA2 breast cancer
genes, the company obtained patents on the
gene sequences and methods of using them to
determine cancer risk. The patents were broad
and interlocking, covering BRCA genomic
DNA, cDNA, methods of diagnosis and systems
detecting mutations. Myriad also filed for diagnostic ‘toolbox’ patents, including two claiming
any DNA primer or probe sharing 15 nucleotides with the wild-type BRCA1 or BRCA2 it
first sequenced. These patents became the heart
of the company.
Since then, the decision to aggressively assert
this intellectual property (IP) has become
synonymous with the Myriad name. Unlike
other diagnostic companies that pursued
cross-licensing opportunities, Myriad was
voraciously litigious, sending cease-and-desist
letters to competitors, clinicians and researchers. It also developed a proprietary database of
rare mutations in the two genes—“variants of
uncertain significance”—that it closed to outside researchers in 2004. Access to healthcare
was another flashpoint. It charged as much as
$4,000 for its flagship test BRCAnalysis—not
uniformly covered by health insurers—where
similar, unpatented tests cost as little as $100.
Civil libertarians, bioethicists and advocacy
groups argued that this squeezed patients seeking BRCA sequencing into a single, high-priced
option. From a business perspective, however,
Myriad’s strategy paid off handsomely. Between
1997 and 2013, Myriad sold around one million
tests and generated $2 billion in revenue, 80% of
it coming from its BRCAnalysis product.
In 2009, these business practices led a group
of patients, physicians and public interest
groups to challenge Myriad’s patents in court. In
response, the US Court of Appeals invalidated
Myriad’s patents’ method claims in 2012. And
in June 2013, the US Supreme Court invalidated
several claims on the genes themselves. The
Court reasoned that isolated BRCA fragments
were unpatentable “products of nature,” even
though they were “isolated and purified” from
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the surrounding genome. However, the Court
upheld Myriad’s claims on BRCA1 and BRCA2
cDNA on the grounds that such molecules were
not naturally occurring.
Following the ruling, several companies
immediately started offering tests for mutations
in BRCA1/2; Myriad promptly sued them for
patent infringement. In March, a Utah federal
court denied Myriad a preliminary injunction
that would have stopped its competitors from
selling diagnostic tests, accusing Myriad of
thwarting advancements in the field.
Critics of the company expected a death rattle.
But Myriad remains very much alive. Although
its initial patents expire in 2016, market inertia
still provided $613 million in annual revenue
to the company last year (a 23% increase from
2012). Indeed, Myriad has been busy expanding its footprint; it has stepped up its companion
diagnostic program, and the recent $270-million
purchase of Crescendo Biosciences signals a
move away from gene-based to protein-based
diagnostics. Yet Myriad has also continued to
stock its patent portfolio, licensing almost a
dozen university patents on methods of cancer
screening, similar to those invalidated by the US
Court of Appeals for the Federal Circuit.
Meanwhile, the diagnostics landscape has
dramatically changed. Several companies
(InVitae, Ambry and Counsyl) offer multiplex,
whole-exome and whole-genome sequencing
for comparable prices. But two companies stand
out in comparison: GeneDx and Illumina.
GeneDx, founded in 2000 and one of Myriad’s
litigation adversaries, specializes in rare-gene
diagnostics. Today, it offers diagnostic sequencing
for hundreds of disorders, as well as limited multigene panel and whole-exome screening, using
mostly next-generation sequencing technology, at
approximately half of Myriad’s per-gene cost. Its
parent company, Bio-Reference Laboratories, has
reported about $700 million in annual revenues,
with much of that from GeneDx. GeneDx also
has good relationships with all commercial insurers and Medicare. In contrast to Myriad, GeneDx
does not rely on gene or diagnostic patents it uses
in testing, and even filed an amicus brief against
Myriad in its Supreme Court case. Rather, many
of GeneDx’s testing protocols come from freely
available, publicly funded research—‘open source’
genetic testing.
Illumina, meanwhile, has developed a strong
IP portfolio and enforced it aggressively. It is

currently engaged in a number of patent lawsuits over sequencing technology, including
one involving noninvasive prenatal genetic
diagnostics for Down syndrome. But the company—with >$400 million in quarterly revenues
and almost 400% growth in the past five years—
has mostly steered clear of patenting genes or
methods of testing specific disorders. Rather,
it has focused on its sequencing platform. As
a consequence, it is constantly attempting to
better—and outsell—its rivals.
These examples suggest that the genetics diagnostic marketplace is moving in two directions.
The first, like GeneDx, is ‘commodities sequencing’ in which companies—armed with advanced
and faster technologies developed elsewhere—
sequence genes or test for genetic disorders,
picking up market share at ever-decreasing rates.
Patent protection contributes little, if anything,
to commodities-type sequencing, and consumer
attraction is largely based on reputation, branding, cost and insurance coverage.
The other path, illustrated by Illumina, is
to patent technology rather than genes—the
hardware and software behind running the
sequencers once patients’ samples come in the
door. Because advancing sequencing costs a
great deal in upfront engineering—and is easily
copied—sequencing companies, like Illumina,
have largely relied on their patent estate to
police competitors. But they have also mostly
forgone patenting disease-specific applications
of their products. The goal is pure innovation:
faster, more accurate and cheaper sequencing
per nucleotide.
Myriad’s current market position, however,
captures neither of these streams. It has not,
despite its patent losses, come to terms with
single-gene sequencing as a commodities business. Nor has it developed its own sequencing
platform, relying instead on the old-school Sanger
method. The purchase of Crescendo suggests
again that Myriad is attempting to corner a single
diagnostic market on shaky IP. In sum, litigation
and ever-evolving technological and business
landscapes are killing monopoly-priced, singlegene sequencing. As neither a commodities
sequencer nor a sequencing innovator, Myriad
stands alone as the last IP-forward, single-gene
company in a multigene, multiplex world.
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